Biocon Limited
BIOCON.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$477.35B
Close$
$-1.47
100.4% downside
Current Fair Value
100.4% downsideOvervalued by 100.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $477.35 Billion |
|---|---|
| Enterprise Value | $609.32 Billion |
| Dividend Yield | $0.50 (0.14%) |
| Earnings per Share | $2.82 |
| Beta | 0.32 |
| Outstanding Shares | 1,621,839,000 |
Return
| Return on Equity | 1.41% |
|---|---|
| Return on Assets | 0.77% |
| Return on Invested Capital | 2.71% |
Valuation & Multiples
| P/E Ratio | 102.76 |
|---|---|
| PEG | 29.41 |
| Price to Sales | 3.3 |
| Price to Book Ratio | 1.51 |
| Enterprise Value to Revenue | 3.52 |
| Enterprise Value to EBIT | 44.66 |
| Enterprise Value to Net Income | 123 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$1.01
Average shareholder expectationRevenue Estimate
$44.73 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.96
Average shareholder expectationRevenue Estimate
$45.96 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biocon Limited
16,447 employees
CEO: Shreehas Pradeep Tambe MTech Biocon Limited is a biopharmaceutical firm engaged in the manufacturing of pharmaceutical goods, including both medicinal chemical compounds and botanical derivatives. The company's operations are segmented across Generics, innovative No...